This article was reviewed by Darragh O’Carroll, MD. Prostate-specific antigen (PSA) is a term you’ll probably become familiar with once you start getting screened regularly for prostate cancer ...
Speakers discussed the disparities in prostate-specific antigen (PSA) screening rates among different racial groups and explored the potential of free PSA percentage as a predictive marker for future ...
Tribune Content Agency on MSN
What is a PSA test and how is it used?
In this two-part series, we'll describe the PSA test-- how it's used, and how doctors perform next steps in the event of an abnormal reading. Our first post addresses PSA screening for prostate cancer ...
Biochemical recurrence is when your PSA level starts to rise after finishing prostate cancer treatment, and it may sometimes indicate metastatic disease. Biochemical recurrence is a term for when your ...
High comorbidity as a predictor of poorer survival and ARPI efficacy in metastatic prostate cancer. Real-world characteristics of long-term survivors with metastatic castration-resistant prostate ...
Opportunistic prostate cancer screening can lead to overdiagnosis of indolent diseases and invasive procedures. A cohort study suggested that a low baseline PSA level in midlife was associated with a ...
Dr. Barry W. Goy explains how to interpret PSA levels after prostate cancer treatment and how to manage recurrence based on disease progression. Among patients with intermediate-risk prostate cancer, ...
In real-world patients with mHSPC, a PSA cutoff of 0.2 ng/mL after 6 to 12 months of intensified hormone therapy predicts survival outcomes. An absolute PSA level of 0.2 ng/mL or more at 6 to 12 ...
Routine PSA testing is not recommend by the USPSTF for men 70 and older, a group expected to derive little benefit. Similar to trends in the U.S., this U.K. study found that a high number of older men ...
Credit: Getty Images Findings have implications for counseling patients treated with radiation therapy plus ADT in routine clinical practice. PSA levels of 0.1 ng/mL or higher within 6 months of ...
Higher persistent PSA levels post-surgery were linked to increased mortality risk, with 8-year prostate cancer–specific mortality reaching 13.86% for a prostate-specific antigen (PSA) ≥ 1 ng/mL. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results